Today, Fool.com health-care analysts Brenton Flynn and David Williamson discuss the ESMO conference in Austria and the focus on an underserved market at the moment -- pancreatic cancer.
Brenton looks at Threshold Pharmaceuticals, which has some potential offerings in this space but still saw shares dive today. He believes this is more related to Celgene's related drug, which has received outsized investor optimism of late. Therefore, Threshold's drop is probably more the product of buzz about a rival that material weakness in the company itself.
When it comes to do-or-die business, the biotech industry takes the cake. Arena Pharmaceuticals is one recent success story in the industry after gaining FDA approval for its innovative obesity drug. While the future looks bright for Arena, there are still plenty of obstacles ahead. In our brand-new premium research report on Arena Pharmaceuticals, we walk investors through the must-know opportunities and threats facing the company. Since key news can develop quickly, we're also including a full year of updates for those who sign up. Click here now to learn more.
